Welcome to our dedicated page for Dalrada Financl news (Ticker: DFCO), a resource for investors and traders seeking the latest updates and insights on Dalrada Financl stock.
Dalrada Technology Group, Inc., formerly Dalrada Financial Corporation, reports developments tied to its role as a multinational holding company focused on technology, health care, and environmental sustainability. Company news has covered the completed name and ticker change, clean-energy heat pump activity, semiconductor deposition products, specialty pharmacy services, and governance updates.
Recurring operating themes include Dalrada Climate Technology heat pump and energy-sustainability systems for industrial and residential uses, Deposition Technology thin-film deposition and plasma spectroscopy products for semiconductor and related markets, and Genefic Specialty Pharmacy prescription, specialty pharmacy, patient advocacy, and support services. Updates also address facilities, customer contracts, board and officer appointments, audit matters, and capital-structure disclosures.
Dalrada Financial (OTCQB:DFCO) announced that its Chairman and CEO, Brian Bonar, has been named the 2024 CEO of the Year by the San Diego Business Journal (SDBJ) for Dalrada's business category. The award was presented at a special ceremony in Torrey Pines, San Diego.
Bonar was recognized for his individual work and leadership, which has led to Dalrada making significant impacts in climate technology and healthcare. The company focuses on developing advanced solutions such as commercial and home heat pumps, as well as providing accessible healthcare and specialty pharmaceuticals.
This recognition highlights Bonar's commitment to solving global challenges and driving Dalrada's growth both locally and globally. The award and feature in SDBJ's special edition further solidify Dalrada's position as an innovative leader in its field.
Dalrada Financial (OTCQB:DFCO) CEO Brian Bonar shared insights and updates in a new interview with SmallCapVoice. Key highlights include:
- Bonar's CEO of the Year Award from San Diego Business Journal
- Opportunities in New York City due to Local Law 97
- Dalrada's appointment to the Minority Business RoundTable (MBRT)
Bonar discussed the potential impact of NYC's Local Law 97, which aims to reduce greenhouse gas emissions in buildings. He noted that Dalrada's heat pump technology could capture a significant market share in replacing gas boilers, potentially generating $60 million in revenue over 18 months with just 1% market penetration. Bonar also anticipates revenue from government opportunities through MBRT starting in the first quarter of next year.
Dalrada Financial (OTCQB: DFCO) has been invited to join the Minority Business RoundTable (MBRT), a prestigious nonprofit organization led by Roger Campos. This membership allows Dalrada unique access to business opportunities in public, private, and government sectors, enhancing its influence and reach globally. Dalrada’s gold-level sponsorship underscores its commitment to a lasting partnership with MBRT. CEO Brian Bonar highlighted the potential for increased awareness and credibility among policymakers, while Campos praised Dalrada's innovative contributions to local and global economies. This strategic move aligns with Dalrada's mission to effect positive change through its technological solutions in climate and healthcare.
Dalrada Financial (OTCQB: DFCO) announced that its healthcare subsidiary, Genefic, has acquired IV Services, , a leading pharmaceutical and infusion management company. This acquisition strengthens Genefic’s market position by expanding its sales and operational footprint, increasing top-line revenue, and enhancing patient care capabilities. The acquisition is non-dilutive to shareholders and allows Genefic to enter the $42 billion global infusion pharmacy management market, which is expected to grow to $70 billion by 2030. Genefic gains new regional presence in Louisiana and Mississippi, complementing its existing operations in several other U.S. states.
Dalrada Financial (OTCQB: DFCO) filed a Form 10-Q for Q3 2024, revealing a revenue of $10.3 million, driven primarily by its pharmaceutical subsidiary, Genefic Specialty Pharmacy. Genefic accounted for $8.6 million, an 80% increase from Q3 2023 and a 95.5% rise from the previous quarter. The company also converted $13.3 million of affiliate debt to Series I preferred shares, reducing net losses to $2.9 million, the lowest since 2021. CEO Brian Bonar emphasized ongoing efforts to clear debt and reduce expenditures, with a net equity of $8.8 million. Dalrada anticipates continued growth in Q4 and a year-over-year revenue increase by the end of fiscal 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.